Trinidad and Tobago vs Uruguay: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Trinidad and Tobago
97.0%
in 2025
Uruguay
97.0%
in 2025
Trinidad and Tobago rank
17th
Uruguay rank
17th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Trinidad and Tobago
- Uruguay
How they compare
Trinidad and Tobago currently reports 97.0% against 97.0% in Uruguay, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Uruguay ahead.
Trinidad and Tobago ranks 17th and Uruguay ranks 17th of 194 countries.
Uruguay has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Trinidad and Tobago | Uruguay | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 68.4% | 93.4% | 25.0% | Uruguay |
| 2020s | 94.3% | 94.8% | 0.5% | Uruguay |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Trinidad and Tobago or Uruguay?
- Trinidad and Tobago, at 97.0% against 97.0% in Uruguay as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Trinidad and Tobago and Uruguay?
- 0.0%, with Trinidad and Tobago ahead.
- How many years of comparable data are there for Trinidad and Tobago and Uruguay?
- 18 years are reported by both, from 2008 to 2025.
- How do Trinidad and Tobago and Uruguay rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Trinidad and Tobago ranks 17th and Uruguay ranks 17th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.